Nanoflex Robotics, a pioneer in magnetically controlled medical soft robotics, has achieved an initial USD12 million in funding. The company will use the funding to bring its first-generation system to market and to accelerate development of new neuro-interventional products. Nanoflex is a medtech spin-off from ETH Zurich accelerated at Wyss Zurich. The financing round is […]
With the transformation into an independent cooperative bank, Raiffeisenbank Zürich has formed a new board of directors of six members. MLL Legal partner Karin Oberlin has been appointed vice president as of January 2023. Karin
Independent private bank Cité Gestion merged with Geneva based multi-family office Sartus Capital expending its total asset under management around CHF 7 billion. Sartus Capital was founded in 2016 and acquired by its management in 2021. From the
As we have informed here, the Helsinn Group has closed a financing agreement with Oberland Capital Management. In this sense, VISCHER has advised Oberland Capital Management on its financing agreement with the Ticino based group.
Homburger has advised Raiffeisen Schweiz Genossenschaft on all legal, regulatory and tax aspects of the spin-off of its 6 branches into independent Raiffeisen banks. The team was led by René Bösch (financial market regulation) and
Swiss proptech Properti has successfully completed its Pre-Series A financing round. The startup received a total of CHF three million. This brings the company’s total capital raised in the past 12 months to over CHF 10
Niederer Kraft Frey advised Diebold Self-Service Solutions, a member of the Diebold Nixdorf group, as Swiss counsel on the refinancing of certain debt and on the provision of USD 400 million in new capital for the
UBS Group successfully completed its issuance of USD 1.75 bn in aggregate principal amount of Fixed Rate/Fixed Rate Callable Senior Notes due January 2027 and USD 2.25 bn in aggregate principal amount of Fixed Rate/Fixed Rate
Advestra advised a group of finance parties as to matters of Swiss law on the refinancing of certain debt and on the provision of USD 400 million in
On January 5, 2023, BioVersys announced that the AMR Action Fund has joined existing investors of BioVersys, extending the total proceeds of the Series C round to CHF 32.6 million. The Swiss pharma company represents the first European-based
